卒中后抑郁的治疗

刘鶠 霜1, 李 震2, 谢金 洙1
1.云南中医药大学中药学院 云南省昆明市 650500 2.昆明医科大学第四附属医院普外三科 云南省昆明市 650500

摘要

目的：卒中后抑郁(PSD)影响在任何时候遭受卒中的个体，阻碍卒中患者的预后增加卒中的复发率，如果不及早治疗会增加死亡率。卒中幸存者中至少有1/3人患有PSD。尽管已经意识到了它的负面影响，但是理解PSD的发病机制仍然具有挑战性。PSD的确切病理生理学尚不清楚，但其复杂性已明确显示，涉及单胺、谷氨酸能系统和神经炎症等机制的功能障碍。目前PSD治疗的有效率约为所有病例的30-40%。在这篇综述中，我们概述了目前治疗PSD的药物方法。

关键词

药物疗法；其他疗法；卒中后抑郁；综述

参考

[1]Feigin, V., et al., World Stroke Organization (WSO): Global Stroke Fact Sheet 2022. International journal of stroke : official journal of the International Stroke Society, 2022. 17(1): p. 18-29.[2]Tay, J., R. Morris, and H. Markus, Apathy after stroke: Diagnosis, mechanisms, consequences, and treatment. International journal of stroke : official journal of the International Stroke Society, 2021. 16(5): p. 510-518.[3]Li, X. and C. Zhang, Comparative efficacy of nine antidepressants in treating Chinese patients with post-stroke depression: A network meta-analysis. Journal of affective disorders, 2020. 266: p. 540-548.[4]Cravello, L., C. Caltagirone, and G. Spalletta, The SNRI venlafaxine improves emotional unawareness in patients with post-strokedepression. Human psychopharmacology, 2009. 24(4): p. 331-6.[5]Liu, Z., L. Qin, and G. Xu, Meta-analysis on effectiveness and safety of bupropion hydrochloride sustained-release tablets and fluoxetine tablets in treatment of depression. Journal of Jilin University Medicine Edition, 2015. 41(1): p. 140-144.[6]Li, F. and D.X. Gu, Treatment for post-stroke depression. Chinese Journal of Clinical Rehabilitation, 2006. 10(38): p. 129-132.[7]Tan, S., et al., Efficacy and Safety of Citalopram in Treating Post-Stroke Depression: A Meta-Analysis. European neurology, 2015. 74: p. 188-201.[8]Ohgi, Y., T. Futamura, and K. Hashimoto, Glutamate Signaling in Synaptogenesis and NMDA Receptors as Potential Therapeutic Targets for Psychiatric Disorders. Current molecular medicine, 2015. 15(3): p. 206-21.[9]Phillips, J., et al., Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial. The American journal of psychiatry, 2019. 176(5): p. 401-409.[10]López-Valdés, H., et al., Memantine enhances recovery from stroke. Stroke, 2014. 45(7): p. 2093-2100.[11]Schoevers, R., et al., Oral ketamine for the treatment of pain and treatment-resistant depression†. The British journal of psychiatry : the journal of mental science, 2016. 208(2): p. 108-13.[12]Gao, Z., Y. Wang, and H. Yu, A Chinese Classical Prescription Chaihu Shugan Powder in Treatment of Post-Stroke Depression: An Overview. Medicina (Kaunas, Lithuania), 2022. 59(1).[13]卢亚奇, et al., 何华教授治疗脑卒中后抑郁经验总结. 中医临床研究, 2021(013-024).[14]Zhen, K., et al., Efficacy and safety of Buyang Huanwu Decoction in the treatment of post-stroke depression: A systematic review and meta-analysis of 15 randomized controlled trials. Frontiers in neurology, 2022. 13: p. 981476.